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Abstract
Peripartum cardiomyopathy (PPCM) is defined as idiopathic cardiomyopathy which occurs at the end of pregnancy or 
in the first few months after delivery, with symptoms of heart failure (HF) secondary to left ventricular dysfunction, and 
at the same time there is no other cause for this condition. The pathomechanism of the disease has not yet been fully 
understood, but it is probably based on the interaction of complex factors. The clinical course of PPCM varies from life-
-threatening acute heart failure to mild symptoms resembling the symptoms typical of the perinatal period. In Europe, 
PPCM is a rare disease but there are areas of the world where it occurs in one in every 300 cases. The treatment of PPCM 
is similar to that of HF with reduced ejection fraction. However, it is important to exclude drugs with teratogenic effects 
during pregnancy. The inclusion of bromocriptine in PPCM therapy seems to be justified, and in some cases improves 
the prognosis.
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Introduction
The first reports of peripartum cardiomyopathy (PPCM) 
were presented in the mid-19th century when Virchow et 
al. [1] described a number of post-mortem examinations 
of women who had died during the perinatal period. At that 
time, the researchers did not know the cause of death, but 
they noticed that the patients had myocardial degeneration. 
It took several decades before Gouley et al. [1] associated 
the perinatal period with cardiomyopathy in 1937. In their 
study, seven cases of pregnant patients with acute heart 
failure (HF) were described, of whom four died. Dilated 
cardiomyopathy at a late stage of pregnancy was charac-
teristic for each case, which persisted also after delivery. 
Post-mortem examinations of deceased patients showed 
myocardial hypertrophy with areas of severe necrosis and 
fibrosis. In 1971, PPCM was named for the first time by 
Demakis and Rahimtooli [1, 2]. New criteria for PPCM 
have been developed in subsequent years thanks to the 
development of diagnostic techniques that include echo-
cardiography and molecular biology, and the discovery of 
new biomarkers. This article presents the current state of 
knowledge regarding PPCM.
Definition of PPCM
The current definition of PPCM was created by the Heart 
Failure Association of the European Society of Cardiology in 
2010. It is idiopathic cardiomyopathy, which manifests as 
HF secondary to left ventricular dysfunction without other 
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including cathepsin D which is responsible for the formation 
of a prolactin shorter form (16 kDa). It has been shown that 
in women with PPCM, the level of STAT-3 protein expression 
is reduced, and the production of 16 kDa prolactin is increa-
sed [9]. One of the new strategies for treating PPCM is based 
on this knowledge. It involves the addition to standard HF 
therapy of bromocriptine, a prolactin-inhibitor. Currently, the 
effects of therapy are satisfactory, and the 2018 guidelines 
of the European Society of Cardiology (ESC) assigned the 
class of recommendation IIa for bromocriptine treatment, 
with the reliability of data at level C [10].
sFLT1
At the beginning of pregnancy, the process of angiogenesis 
is increased. However, this tendency changes with the pas-
sage of time and especially in the perinatal period when 
the placenta begins to secrete anti-angiogenic substances. 
These include a soluble fms-like tyrosine kinase-1 (sFLT1) 
[11]. In a normal pregnancy, these are physiological pro-
cesses and do not cause any complications. However, 
there may be subclinical dysfunction of cardiomyocytes in 
abnormal conditions of sFLT1 excess or when the mecha-
nisms protecting the heart against antiangiogenic factors 
are compromised. PPCM patients have been shown to have 
a significantly elevated level of sFLT1. Moreover, multiple 
pregnancy and pre-eclampsia both increase the secretion 
of this antiangiogenic. This may explain why multiparous 
women with pre-eclampsia are more often diagnosed with 
PPCM [10]. An increase of the angiogenesis process by 
the administration of vascular endothelial growth factor 
(VEGF) has been proposed for PPCM treatment. Previous 
attempts were made only on mice, and the use of VEGF 
alone did not give the expected results. Only treatment 
with a combination of VEGF and bromocriptine turned out 
to be satisfactory [12].
causes. It occurs at the end of pregnancy or in the first few 
months after delivery. For a diagnosis of PPCM, the ejection 
fraction should be ≤ 45%, although there is no obligation to 
document the enlargement of the left ventricle dimension.
PPCM is a diagnosis of exclusion. In contrast to the 
previous definition from 2000, it does not take into acco-
unt the exact time interval of the disease (previously it 
needed to occur between the final month of gestation and 
5–6 months after delivery), or specific echocardiographic 
criteria (previously: lower ejection fraction < 45%, and 
shortening fraction < 30% and enlargement end-diastolic 
dimension of the left ventricle cavity > 2.7 cm/m2 of the 
body surface). The current definition is less restrictive, 
thus reducing the chances of missing a patient with this 
disease [3, 4].
Pathogenesis
Probably there is a complex mechanism that causes PPCM, 
and therefore there is no other theory that can explain 
its development. The literature describes many factors 
involved in the development of the disease. Some of the 
more important ones are presented in Table 1 [3, 5–9]. 
This paper describes two pathomechanisms that seem to 
be the most important in PPCM [6].
Prolactin
Physiologically, prolactin with a mass of 23 kDa protects the 
endothelium and promotes angiogenesis. In the period of 
oxidative stress caused by pregnancy for example, a shor-
ter form of 16 kDa with a strong cardiotoxic effect may be 
formed. STAT-3 is a protein responsible for the protection of 
the myocardium by the induction of antioxidant enzymes. 
The disruption of STAT-3 function leads to an intensifica-
tion of oxidative stress and activation of several enzymes, 
Table 1. Major factors involved in the development of peripartum cardiomyopathy (PPCM)
Pathogenesis of PPCM Brief description
Genetic/environmental factors Epidemiological data on the increased incidence of PPCM in some areas and among selected 
ethnic groups, especially Africans or African-Americans [3]. Some studies suggest association 
with familial dilated cardiomyopathy [5, 6]
Infectious/autoimmune factors Presence of the viral genome has been evidenced in cardiomyocytes of women with PPCM  
(31%) [7]
Increase in the concentration of inflammatory markers is observed  in PPCM: TNF-a, interferon g, 
interleukin 6, CRP [8]
Factors related to angiogenesis At the end of pregnancy, the placenta begins to secrete anti-angiogenic substances. In the case 
of impaired cardiac protective mechanisms against anti-angiogenic factors or an excess of these 
factors, subclinical dysfunction of cardiomyocytes may occur [8]
Factors related to prolactin Physiologically, prolactin protects the endothelium and promotes angiogenesis; however, under 
increased oxidative stress caused by pregnancy, short form of prolactin may be generated that is 
toxic to cardiomyocytes [9]
TNF-a — tumor necrosis factor a; CRP — C-reactive protein
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Epidemiology
The prevalence of PPCM is characterised by significant 
geographical variations. In many areas, the actual number 
of cases is unknown and further research is needed. The 
highest density of recognised PPCMs has been recorded 
in Nigeria (1:100 cases) and Haiti (1:300 cases). For 
comparison, the disease affects 1:1,000–1,500 women in 
Germany, 1:1,000 in South Africa and 1:2,500–4,000 in 
the USA [3, 10]. From the cited data described in 2010 by 
Sliwa et al. [3], it is clear that African origins predispose to 
a more frequent occurrence of peripartum cardiomyopathy. 
The average age of PPCM incidence rate is 27–33 years, 
depending on the region. Indeed, compared to older pub-
lications, this average age has increased in recent publi-
cations [3]. In addition, there has also been an increased 
incidence of PPCM over recent years — from 1 in 4,350 
women in 1990–1993 to 1 in 1,229 in 2000–2002. This 
increase may be attributable to several factors: the later 
age at which women are becoming pregnant, an increase 
in the number of multiple pregnancies, developing access 
to methods of assisted reproduction, and increased recog-
nition of PPCM [13].
Clinical presentation
Difficulties associated with making the right diagnosis are 
related to the fact that the clinical picture of PPCM resem-
bles the perceived symptoms typical of the final period of 
pregnancy or the effort associated with the birth itself. 
Often the symptoms do not have a high severity, which 
makes it difficult to make the right diagnosis [3].
The vast majority of patients develop symptoms in the 
first four months after delivery (78%), and only 9% show 
disease onset in the last month of pregnancy. The rema-
ining 13% of cases refer to women diagnosed with PPCM 
earlier than one month before delivery or later than four 
months after delivery [3].
Typical symptoms include shortness of breath, swel-
ling of the lower limbs, orthopnoea, fatigue, chest pain, 
reduced exercise tolerance, and heart palpitations. In the 
study of Patel et al. [14] from 2015, 19 Swedish patients 
were chosen (according to the ESC criteria from 2010) 
to determine the most common symptoms of PPCM. All 
subjects reported more than one symptom. The most 
common complaints were: dyspnoea (18 out of 19), fluid 
retention (15 out of 19), excessive fatigue (14 out of 19), 
and a persistent cough (eight out of 19). The study also 
looked at mental symptoms: 11 out of 19 women reported 
at least one of the following symptoms: feelings of una-
voidable death (seven), panic attacks (five), anxiety (five) 
or fear (fear) [14].
Diagnosis of PPCM
A diagnosis of PPCM is based on the exclusion of other 
HF causes [15]. The disease should be suspected in all 
peripartum women with symptoms of HF or those who 
have a delay in returning to their pre-pregnancy baseline 
[16]. Two key studies that must be performed when PPCM 
is suspected are echocardiography and N-terminal pro-B-
-type natriuretic peptide (NT-proBNP) or B-type natriuretic 
peptide (BNP). Further testing for PPCM is necessary if the 
left ventricular ejection fraction (LVEF) is ≤ 45% or the level 
of natriuretic peptides is increased [12]. The useful tests 
include chest radiograph (this can show enlargement of 
the heart, low blood circulation and pleural effusion), and 
ECG (left ventricular overload, non-specific changes in ST 
segments, prolonged QT interval or large QRS complexes). 
MRI may be performed as an addition to echocardiography 
[17] and a myocardial biopsy in suspected HF with infec-
tious aetiology [16].
In addition, newly discovered biomarkers appear to 
be promising in women suffering from PPCM and could 
be helpful in the differential diagnosis. Selected ones are 
presented in Table 2 [8, 18, 19].
Treatment
According to the latest guidelines of the European Cardiac 
Society (ESC) from 2018, the treatment of PPCM does not 
Table 2. Selected biomarkers for peripartum cardiomyopathy (ad-
apted from [8, 18, 19])
Biomarker’s name Level in PPCM
micro-RNA 146 Increased
Endothelial cells and  
monocyte microparticles
Increased circulating levels in the 
blood
sFLT1 Increased in late pregnancy and rapid 
decrease after delivery (the threshold 
values are difficult to define)
Inflammatory proteins: 
CRP, TNF-a, interferon g, 
interleukin 6
Increased
Prolactin 16 kDa Increased
Catepsin D Increased
Relaxin 2 Decreased (the threshold values 
are difficult to define)
Oxidized LDL Increased
TGF-b1 Decreased
PPCM — peripartum cardiomyopathy; sFLT1 — soluble fms-like tyrosine kinase-1; CRP — C-reactive 
protein; TNF-a — tumor necrosis factor a; LDL — low-density lipoprotein; TGF-β1 — transforming 
growth factor β1
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Table 3. Selected drugs used in peripartum cardiomyopathy (adapted from [15, 16])
Class of drugs Non-proprietary name Comment
ACEI Captopril Contraindicated during pregnancy (risk of kidney damage, mal-
formations and hypotension in the fetus)Enalapril
Ramipril There is no data on the risk during pregnancy
Sartans Candesartan Contraindicated during pregnancy and breast-feeding
Valsartan
Potassium-sparing diuretics Spironolactone Contraindicated during pregnancy and breast-feeding (possible 
antiandrogenic effects in the fetus)
Eplerenon Negative effects have not been fully understood (category B 
according to the FDA classification)
Beta-blockers Extended-release metoprolol Low risk of bradycardia and respiratory failure in the newborn 
Cardioselective drugs preferred during pregnancyCarvedilol
Atenolol Risk of low birth weight and fetal bradycardia if administered  
in II or III trimester
Vasodilators Hydralazine In combination with nitrates as a safe alternative to ACEIs/ 
/sartans during pregnancy
Nitroglycerin Risk of hypotension
Diuretics Hydrochlorothiazide Risk of reduced placental blood flow. Use only in patients with 
signs of congestion in the pulmonary circulation
Furosemide Use only in patients with signs of congestion in the pulmonary 
circulation
Inotropes Digoxin Consider in patients with low EF. Keep in mind the risk of toxici-
ty when used in high doses
Dobutamine Insufficient evidence for safe use during pregnancy
Milrinone
Anticoagulants Warfarin Risk of abnormal development of the bones of the nose, 
limbs, joint cartilage, as well as the risk of ear, eye and central 
nervous system anomalies
Low-molecular-weight heparin Use in patients treated with bromocriptine. Implement treat-
ment if EF < 35%
Prolactin inhibitors Bromocriptine Increased thromboembolic risk; recommendation class IIa, 
level of evidence C
Dosing schedule: 2.5 mg twice daily for 2 weeks, and then  
2.5 mg once daily for 6 weeks
Heart rate lowering agents Ivabradine Use in patients with high heart rate
Contraindicated during pregnancy and breast-feeding
ARNI Sacubitril/valsartan Contraindicated during pregnancy and breast-feeding
Red — drugs contraindicated during pregnancy, blue — there are no data indicating fetal toxicity; ACEI — angiotensin-converting enzyme inhibitors; ARNI — angiotensin receptor neprilysin inhibitors; EF — ejec-
tion fraction; FDA — Food and Drug Administration
deviate from the recommendations used in acute HF, car-
diogenic shock, or chronic HF of a different aetiology. It is 
important to exclude drugs that may have a harmful effect 
on the developing foetus or those that are contraindicated 
during breastfeeding [angiotensin-converting enzyme 
inhibitors (ACEI), sartans, angiotensin receptor neprilysin 
inhibitor (ARNI), potassium-sparing diuretics, warfarin, and 
ivabradine] [15]. Selected contraindicated medications are 
presented in Table 3 [15, 16]. A pregnant woman with PPCM 
should be under the combined care of a cardiologist and 
an obstetrician, and possible complications for the foetus 
should be observed in ultrasound [3].
Pregnancy in a patient with cardiovascular disease is al-
ways at high risk of complications. Therefore, it is necessary 
to inform the patient that the frequency of ultrasonography 
of the foetus will be different from the standard procedure 
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for an uncomplicated pregnancy. Until the 28th week of 
pregnancy, the test should be performed once a month for 
patients in New York Heart Association (NYHA) class I and II 
and every two weeks or more often for those in NYHA class 
III and IV. After the 28th week of pregnancy, the examination 
should take place every week until delivery [20].
In case of acute severe HF, one should bear in mind the 
need for premature termination of pregnancy with access 
to a mechanical circulatory support system (MCS) and the 
implementation of lung maturation accelerating treatment 
in the foetus beyond the 23rd week of pregnancy + 5 days 
[15]. Furthermore, the inclusion of intensive acute HF 
treatment is obligatory.
The principles of PPCM treatment are presented in 
Figure 1 [15], including the period before and after delivery.
In addition to the standard procedure, it is also worth 
paying attention to the possibility of bromocriptine inclu-
sion for the treatment of PPCM. According to the 2018 ESC 
guidelines, the addition of bromocriptine to standard HF 
therapy favourably affects left ventricular function and 
improves prognosis in women with a severe PPCM course 
[15]. For an uncomplicated PPCM, a dose of 2.5 mg per 
day is recommended for at least a week. Patients with 
ejection fraction < 25% and/or cardiogenic shock may 
be considered for a therapy of 2.5 mg twice daily for two 
weeks, followed by 2.5 mg once daily for six weeks. When 
treating with bromocriptine, it is important to remember 
about anticoagulation (prophylactic doses of low molecu-
lar weight heparin) [15]. Studies have shown very good 
treatment effects: in a six-month follow-up, total recovery 
Figure 1. Algorithm for the management of peripartum cardiomyopathy (PPCM) (adapted from [15]); SBP — systolic blood pressure; HR — 
heart rate; RR — respiratory rate; SpO2 — arterial blood oxygen saturation; ScvO2 — central venous oxygen saturation; MCS — mechanical 
circulatory support; ECG — electrocardiography; HF — heart failure; ACEI — angiotensin-converting enzyme inhibitors; WCD — wearable 
cardioverter-defibrillator; LVEF — left ventricular ejection fraction
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with restored left ventricular function, which remain stable 
after HF medication reduction, an annual follow-up visit is 
recommended for the next 10 years [22].
Prognosis
Although the clinical course of PPCM may vary considerably, 
the general prognosis of patients after normal treatment 
is good. About 50% of women have a full recovery (defined 
as LVEF > 55% and NYHA class I), while 35–40% improve 
(defined as an increase of LVEF by more than 10% and 
improvement of at least one NYHA class) [12]. Based on 
the literature, mortality varies between 2% in Germany 
and 12.6% in South Africa 1–6 months after delivery. The 
mortality rate between six and 12 months after childbirth 
ranges from 4% to 14%; for women of African descent it 
is 12–14%. Subsequently, in the range of 1–5 years, mor-
tality in a population of 182 women in the United States 
was 7% at the time of the follow-up examination in the 
19th month. For African-American patients, this rate was 
higher and in the second year of the study, the mortality 
rate was 28% in South Africa, 16% in the USA and 15% in 
Haiti. Between the second and the fifth year, these values 
varied significantly depending on the region, and ranged 
from 0–6%, in France and the United States, to 15–30% 
in China, Brazil, Turkey, South Africa and the Philippines. 
There is little data available for a prognosis of more than 
five years. In this period, mortality is 7–16% in India and 
8.3% in Malaysia [8].
In addition, there have as yet been no publications on 
the long-term prognosis for patients after heart transplan-
tation and with an implanted left ventricle assist device 
(LVAD). Table 4 summarises the most important information 
from work on PPCM [23–31].
Conclusions
In recent years, the awareness about PPCM has risen, and 
a growing interest was sparked by recent publications. 
Although data on the extent of disease prevalence in most 
parts of the world is lacking, and many issues remains 
unexplained, in recent years a number of findings have 
been made that have contributed to improved PPCM diag-
nosis and treatment. New biomarkers have been proposed, 
new underlying mechanisms contributing to its onset have 
been discovered, and bromocriptine treatment has been 
introduced. It has been documented that bromocriptine 
in PPCM therapy is beneficial, although more research is 
needed on the use of this medicine.
was found in 60% of cases, with 0% mortality. Patients did 
not require a transplant or the use of cardiac devices [21].
Prophylaxis and further management
Contraception 
Patients who have been diagnosed with PPCM are of 
childbearing age. The associated risk of PPCM recurrence, 
especially in the absence of ejection fraction parameters 
normalisation, makes it necessary to implement an effec-
tive and relatively safe method of contraception [3].
According to the 2018 European Society of Cardiology 
(ESC) guidelines [15], ethinyl oestradiol drugs are con-
traindicated in patients with PPCM due to the high risk 
of thromboembolic complications. Sliwa et al. described 
the possible consequences [3]. In their opinion, oral two-
-component agents combining oestrogen and progesterone 
derivatives are not a good method due to the adverse 
thromboembolic profile. Gestagens are an alternative to 
these measures. It is believed that they have little effect on 
the risk of thromboembolism in the case of subcutaneous 
implants and injections, and pose no thromboembolic risk 
in oral form and in intrauterine devices. The safety profile 
and high efficacy of levonorgestrel available in the form of 
an intrauterine system and a subcutaneous implant are 
particularly appreciated [15].
It should be remembered that the right form of contra-
ception is the key to prevent the recurrence of PPCM. It is 
necessary to present a patient with possible ways of preven-
ting another pregnancy. During the choice of optimal contra-
ceptive therapy, we are obliged to take into account both the 
medical indications and the comfort in use for the woman.
Breastfeeding
In a case of diagnosed PPCM, breastfeeding cessation sho-
uld be considered. Persistent high levels of prolactin during 
lactation may adversely affect the course of the disease and 
prognosis of the patient. Therefore, patients with significant 
left ventricular systolic dysfunction should not breastfeed 
and should be considered for bromocriptine. An exception 
to the above recommendation is a situation where a small 
impairment of left ventricular systolic function coexists 
with poor access to modified milk and unfavourable envi-
ronmental conditions. In these circumstances, sustaining 
breastfeeding seems to be justified [22].
Follow-up
It is recommended that echocardiography should be perfor-
med every six months until LVEF returns > 50%. In women 
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Streszczenie
Kardiomiopatię połogową (PPCM) definiuje się jako idiopatyczną kardiomiopatię, która występuje pod koniec ciąży lub 
w pierwszych kilku miesiącach po porodzie z objawami niewydolności serca (HF) wtórnie do zaburzeń czynności lewej 
komory i jednocześnie nie stwierdza się żadnej innej przyczyny tego stanu. Patomechanizm choroby nie został w pełni 
poznany, natomiast prawdopodobnie opiera się na działaniu złożonych czynników. Przebieg kliniczny PPCM jest zróż-
nicowany: od zagrażającej życiu ostrej HF po łagodne objawy naśladujące dolegliwości charakterystyczne dla okresu 
okołoporodowego. W Europie PPCM jest dość rzadką chorobą, natomiast są rejony, gdzie występuje z częstością 1/300 
przypadków (Haiti). Leczenie PPCM jest podobne jak dla HF z obniżoną frakcją wyrzutową, jednak ważne jest wyklu-
czenie leków o działaniu teratogennym w trakcie trwania ciąży. Włączanie bromokryptyny do terapii PPCM wydaje się 
zasadne i w niektórych przypadkach poprawia rokowanie.
Słowa kluczowe: kardiomiopatia połogowa, PPCM, niewydolność serca, ciąża, bromokryptyna
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